Stocks News

LAST PRICE
2.5100
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
2.4600/ 94
Ask / Lots
2.5100/ 16
Open / Previous Close
--- / 2.5100
Day Range
---
52 Week Range
Low 1.9000
High 8.7500
Volume
6,470
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Rani Therapeutics to Participate in Upcoming Investor Conferences, from 16 hours ago by Dow Jones
  16 hours ago by Dow Jones
  Companies Mentioned: RANI
  
  Rani Therapeutics to Participate in Upcoming Investor Conferences
  
  SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in three upcoming conferences. These conferences include:
Oct 18, 2024
- DJ Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 7:02AM ET on Friday Oct 18, 2024 by Dow Jones
  7:02AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: RANI
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RANI/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 18, 2024 07:02 ET (11:02 GMT)
Oct 17, 2024
- Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist, from 8:00AM ET on Thursday Oct 17, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 17, 2024 by Dow Jones
  Companies Mentioned: RANI
  
  Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
  
  -Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection -
Oct 15, 2024
- Top Midday Decliners, from 2:05PM ET on Tuesday Oct 15, 2024 by MT Newswires
  2:05PM ET on Tuesday Oct 15, 2024 by MT Newswires
  Companies Mentioned: SEEL, ASML, RANI
  02:05 PM EDT, 10/15/2024 (MT Newswires) -- Rani Therapeutics (RANI) said Tuesday it priced a registered direct offering of securities, targeting gross proceeds of about $10 million. Shares slumped 23%, with intraday trading volume at over 16.7 milli...
- Rani Therapeutics Shares Fall After $10 Million Registered Direct Securities Offering Priced, from 1:40PM ET on Tuesday Oct 15, 2024 by MT Newswires
  1:40PM ET on Tuesday Oct 15, 2024 by MT Newswires
  Companies Mentioned: RANI
  01:40 PM EDT, 10/15/2024 (MT Newswires) -- Rani Therapeutics Holdings (RANI) shares fell 23% in recent Tuesday trading after the company priced a registered direct offering of securities for gross proceeds of about $10 million. The company agreed to...

Today
- DJ Vigil Neuroscience Price Target Maintained With a $17.00/Share by HC Wainwright & Co., from 36 minutes ago by Dow Jones
  36 minutes ago by Dow Jones
  Companies Mentioned: VIGL
Yesterday
- Press Release: Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: VIGL
- Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: VIGL
Nov 5, 2024
- Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference, from 7:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  7:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: VIGL
Oct 31, 2024
- -- Earnings Flash (INMB) INMUNE BIO Reports Q3 Loss $-0.60, from 4:12PM ET on Thursday Oct 31, 2024 by MT Newswires
  4:12PM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: INMB
- *DJ INmune Bio 3Q Loss/Shr 60c >INMB, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
  4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: INMB
- INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
  4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: INMB
Oct 30, 2024
- --HC Wainwright Starts FibroBiologics With Buy Rating, $12 Price Target, from 12:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  12:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: FBLG
- DJ FibroBiologics Initiated at Buy by HC Wainwright & Co., from 8:56AM ET on Wednesday Oct 30, 2024 by Dow Jones
  8:56AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: FBLG
Oct 29, 2024
- DJ FibroBiologics CFO Andersen Resigns, from 7:38PM ET on Tuesday Oct 29, 2024 by Dow Jones
  7:38PM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: FBLG

Rani Therapeutics Holdings Inc
NASDAQ:RANIUnited States

Search Criteria

Yesterday

Rani Therapeutics to Participate in Upcoming Investor Conferences, from 16 hours ago by Dow Jones

Oct 18, 2024

DJ Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 7:02AM ET on Friday Oct 18, 2024 by Dow Jones

Oct 17, 2024

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist, from 8:00AM ET on Thursday Oct 17, 2024 by Dow Jones

Oct 15, 2024

Top Midday Decliners, from 2:05PM ET on Tuesday Oct 15, 2024 by MT Newswires

Rani Therapeutics Shares Fall After $10 Million Registered Direct Securities Offering Priced, from 1:40PM ET on Tuesday Oct 15, 2024 by MT Newswires

Peers Headlines

Today

DJ Vigil Neuroscience Price Target Maintained With a $17.00/Share by HC Wainwright & Co., from 36 minutes ago by Dow Jones

Yesterday

Press Release: Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 5, 2024

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference, from 7:01AM ET on Tuesday Nov 05, 2024 by Dow Jones

Oct 31, 2024

-- Earnings Flash (INMB) INMUNE BIO Reports Q3 Loss $-0.60, from 4:12PM ET on Thursday Oct 31, 2024 by MT Newswires

*DJ INmune Bio 3Q Loss/Shr 60c >INMB, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

--HC Wainwright Starts FibroBiologics With Buy Rating, $12 Price Target, from 12:37PM ET on Wednesday Oct 30, 2024 by MT Newswires

DJ FibroBiologics Initiated at Buy by HC Wainwright & Co., from 8:56AM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 29, 2024

DJ FibroBiologics CFO Andersen Resigns, from 7:38PM ET on Tuesday Oct 29, 2024 by Dow Jones